title: Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires.
abstract: Immunoglobulin gene usage and somatic mutation patterns were studied in 59 patients with splenic marginal zone lymphoma and were correlated with clinical characteristics. Fifty-nine IGHV rearrangements were amplified. IGHV1, IGHV3, and IGHV4 subgroups accounted for 30%, 56%, and 14% of sequences, respectively. IGHV genes most frequently used were IGHV1-2 (n=12), IGHV3-23 (n=15), IGHV3-30 (n=7) and IGHV4-34 (n=5). IGHV was unmutated in 25%. Villous lymphocytes >10% were detected in 50% of patients belonging to the IGHV1-2 group, in 21% of the IGHV3-23 group, and in no patient of the IGHV3-30 group (p=0.05). Liver involvement was present in 50% of the IGHV3-30 group, in 9% of the IGHV3-23 group, and in no patient of the IGHV1-2 group (p=0.04). HCV-serology was positive in 50% of the IGHV3-30 group, in 7% of the IGHV3-23 group, and in 17% of the IGHV1-2 group (p=0.04). The proportion of intermediate and high risk patients according to the SMZL score was higher in the unmutated respect to the mutated group (69% vs 32%, p=0.05). In conclusion, IGHV rearrangement analysis in splenic marginal zone B-cell lymphoma reveals a non-random preference for use of IGHV1-2, IGHV3-23 and IGHV3-30 genes, whose presence differs according to clinical features and prognostic category.
authors.affiliation: Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia - Viale C. Golgi 19, 27100 Pavia, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Arcaini
authors.forename: Silvia
authors.initials: S
authors.lastname: Zibellini
authors.forename: Francesco
authors.initials: F
authors.lastname: Passamonti
authors.forename: Sara
authors.initials: S
authors.lastname: Rattotti
authors.forename: Marco
authors.initials: M
authors.lastname: Lucioni
authors.forename: Rosangela
authors.initials: R
authors.lastname: Invernizzi
authors.forename: Michele
authors.initials: M
authors.lastname: Merli
authors.forename: Silvia
authors.initials: S
authors.lastname: Rizzi
authors.forename: Emanuela
authors.initials: E
authors.lastname: Boveri
authors.forename: Elisa
authors.initials: E
authors.lastname: Rumi
authors.forename: Cesare
authors.initials: C
authors.lastname: Astori
authors.forename: Cristina
authors.initials: C
authors.lastname: Picone
authors.forename: Marzia
authors.initials: M
authors.lastname: Varettoni
authors.forename: Cristiana
authors.initials: C
authors.lastname: Pascutto
authors.forename: Marco
authors.initials: M
authors.lastname: Paulli
authors.forename: Mario
authors.initials: M
authors.lastname: Lazzarino
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016000:Cluster Analysis; D005260:Female; D015326:Gene Rearrangement, B-Lymphocyte, Heavy Chain; D005803:Genes, Immunoglobulin; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000235:genetics* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012306:Risk; D013160:Splenic Neoplasms / Q000235:genetics* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis
chemical_list: D007143:Immunoglobulin Heavy Chains